We evaluated the in vitro activity of piperacillin alone or in combination with the 1-lactamase inhibitor ,ug/ml; and piperacillin-tazobactam (expressed in terms of MIC of piperacillin) 0.5 and 1 (0.03 to 2) Rg/ml.
approximately 10-fold higher inoculum, the following results were obtained, expressed as MICs for 50 and 90%o of strains tested (MIC range): piperacillin, 4 and 16 (0.25 to 32) ,ug/ml; tazobactam, 0.5 and 1 (0.125 to 2) ,ug/ml; and piperacillin-tazobactam (expressed in terms of MIC of piperacillin) 0.5 and 1 (0.03 to 2) Rg/ml.
Tazobactam alone and the combination with piperacillin were more active than piperacillin alone at the higher inoculum.
,-Lactams are widely used in the treatment of bacterial pneumonias. However, when other bacterial pathogens are not readily identifiable, concern for a possible etiologic role of Legionella species often results in the addition of erythromycin to 3-lactams in empirically selected antimicrobial regimens. Several P-lactam antibiotics actually demonstrate activity against Legionella spp. in vitro on various media (9, 11) , but a number of these are ineffective when examined against intracellular Legionella strains in vitro or in animal models of infection with these organisms (3, 13, 14, 16) . A notable exception to these observations is the fact that both clavulanic acid alone and combinations of this agent with either amoxicillin or ticarcillin have demonstrated activity against cell-associated Legionella pneumophila in vitro and in experimental animal models (13, 14, 16) .
In the present study we At either inoculum, rifampin, ciprofloxacin, and clarithromycin were each at least eightfold more active than erythromycin on the basis of MICs for 90% of strains tested. MICs of these drugs were within ranges reported previously (1, 2, (4) (5) (6) . The MIC range and MIC of sulbactam for 50% of strains tested were two-to fourfold lower in our study than previously reported for this drug when tested against Legionella spp. in buffered charcoal-yeast agar medium (5) .
In the present study, the in vitro activity of the ,-lactamase inhibitor tazobactam was equivalent to that of clavulanic acid against the Legionella spp., and results with the latter compound were consistent with previous reports (9, 15) . Both in tissue culture (16) and in a weanling rat model of infection (13, 14) , clavulanic acid has proven effective in reducing numbers of intracellular L. pneumophila organisms. In these studies, neither amoxicillin nor ticarcillin alone showed activity against cell-associated organisms. Furthermore, in an animal model, the combination of clavulanate with either amoxicillin or ticarcillin proved comparable to erythromycin in eradication of organisms within pulmonary alveolar macrophages (13, 14) . A small but significant advantage was noted for the combination of ticarcillin with clavulanic acid compared with clavulanate alone (13) .
Both as a single agent and in combination with piperacillin, tazobactam demonstrated in vitro activity against Legionella spp. comparable to that of clavulanic acid. In view of the fact that clavulanic acid, unlike many other ,B-lactams examined, has shown activity against intracellular L. pneumophila both in vitro and in vivo, it would be of great interest to examine tazobactam alone and in combination with piperacillin in these systems. If it could be demonstrated that ,-lactam antimicrobial agents, such as piperacillin-tazobactam or ticarcillin-clavulanate, which have broad activity against both community-acquired and nosocomial pathogens also effectively inhibit Legionella spp. in vivo and are clinically effective, selection of initial therapy for seriously ill patients with pneumonia might be simplified considerably.
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